Quantum-machine-assisted drug discovery

Yidong Zhou, Jintai Chen, Jinglei Cheng, Gopal Karemore, Marinka Žitnik, Frederic T. Chong, Junyu Liu, Tianfan Fu, Zhiding Liang

Abstract: Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.

The Computational Wall in Pharmaceutical R&D

The pharmaceutical industry is currently hitting a "computational wall." Developing a single drug takes over a decade and billions of dollars, largely because the chemical space of potential compounds is unfathomably large—estimated at $10^{60}$ molecules. Classical computers struggle with two main bottlenecks: quantum accuracy in sub-atomic simulations and the complexity of managing massive, multi-dimensional clinical datasets while maintaining strict privacy.

The traditional drug discovery funnel, highlighting the lengthy timeline and massive reduction in candidate molecules.

Quantum Methodologies for Molecular Design

Because molecules are governed by quantum mechanics, quantum computers are the only "natural" tools to simulate them. The paper reviews a suite of quantum algorithms categorized by their specific advantages:

  • Simulation & Modeling: Techniques like Quantum Phase Estimation (QPE) and the Variational Quantum Eigensolver (VQE) solve electronic structure problems that are exponentially hard for classical machines. This shifts complexity from $O(e^N)$ to polynomial $O(N^4)$.
  • Generative Design: Quantum Generative Adversarial Networks (QGANs) and Quantum Kernels navigate the $10^{60}$ molecule space more efficiently than classical machine learning, enabling true de novo drug design.
Overview of quantum-assisted workflows, including de novo drug design, molecular simulation via VQE, and clinical trial optimization.

Optimizing the Clinical Pipeline

Quantum's utility extends beyond the lab into the business of pharma. The Quantum Approximate Optimization Algorithm (QAOA) is proposed for "portfolio optimization," such as deciding which clinical trial sites to open and how to stratify patient cohorts. Furthermore, Quantum Federated Learning (QFL) introduces a way to train models on sensitive patient data across different hospitals without exposing raw data, overcoming significant privacy hurdles that currently lead to inefficient trial designs.

Key Results and Future Outlook

The integration of quantum systems offers quantifiable advantages:

  • Lead Discovery: A quadratic speedup ($O(\sqrt{N})$) for searching chemical libraries.
  • Clinical Trials: A logarithmic reduction in communication overhead for federated learning and polynomial advantages in combinatorial optimization.

While we are currently in the Noisy Intermediate-Scale Quantum (NISQ) era—limited to simulating small molecules (<10 atoms)—the near-term win lies in using quantum processors as "physics-aware evaluators" within classical pipelines. Future progress toward Fault-Tolerant Quantum Computing (FTQC) and distributed quantum networks will be essential to simulate the large proteins that remain "uncomputable" today.

Summary updated

Abstract

Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.
BibTeX
@inproceedings{zhou2026quantum,
  author = {Yidong Zhou and Jintai Chen and Jinglei Cheng and Gopal Karemore and Marinka Žitnik and Frederic T. Chong and Junyu Liu and Tianfan Fu and Zhiding Liang and Tianfan Fu and Zhiding Liang},
  title = {{Quantum-machine-assisted drug discovery}},
  booktitle = {Npj},
  year = {2026},
  doi = {10.1038/s44386-025-00033-2},
}
Figure